Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism  Mary.

Published byIsak Hansson Modified over 5 years ago

Similar presentations

Presentation on theme: "Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism  Mary."— Presentation transcript:

1 Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism  Mary Eapen, Kwang Woo Ahn, Paul J. Orchard, Morton J. Cowan, Stella M. Davies, Anders Fasth, Anna Hassebroek, Mouhab Ayas, Carmem Bonfim, Tracey A. O’Brien, Thomas G. Gross, Mitchell Horwitz, Edwin Horwitz, Neena Kapoor, Joanne Kurtzberg, Navneet Majhail, Olle Ringden, Paul Szabolcs, Paul Veys, K. Scott Baker  Biology of Blood and Marrow Transplantation  Volume 18, Issue 9, Pages (September 2012) DOI: /j.bbmt Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 The 7-year probability of overall survival for patients who survived longer than 2 years after transplantation with normal T cell function (SCID patients) and >95% donor chimerism (non-SCID PIDD and IEM patients) was 93% for SCID patients, 96% for non-SCID PIDD patients, and 90% for IEM patients. The 9-year probability of overall survival was 92% for SCID patients, 96% for non-SCID PIDD patients, and 88% for IEM patients. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism  Mary."

Similar presentations

Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia  Michael R. Verneris, Mary Eapen,

Reduced-Intensity Conditioning Regimens for Allogeneic Transplantation in Children with Acute Lymphoblastic Leukemia  Michael R. Verneris, Mary Eapen,
Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,

Adverse Clinical Consequences of Hyperglycemia from Total Parenteral Nutrition Exposure during Hematopoietic Stem Cell Transplantation  Patricia M. Sheean,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.

Sirolimus in Combination with Cyclosporine or Tacrolimus Plus Methotrexate for Prevention of Graft-versus-Host Disease following Hematopoietic Cell Transplantation.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation  Navneet S. Majhail, MD, MS, Tejo.
Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplantation Clinical Trials  Ellen M. Denzen, Martha E. Burton Santibáñez, Heather Moore,

Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplantation Clinical Trials  Ellen M. Denzen, Martha E. Burton Santibáñez, Heather Moore,
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children’s Haematology Oncology.

Outcomes of Hematopoietic Stem Cell Transplantation in Primary Immunodeficiency: A Report from the Australian and New Zealand Children’s Haematology Oncology.
Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 

Hematopoietic Cell Transplantation Provides Durable Disease Control in Patients with Double-Hit Lymphoma  Taewoong Choi, Murali K. Kodali, Wen-Kai Weng 
Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S

Annalisa Ruggeri, Mary Eapen, Andromachi Scaravadou, Mitchell S
Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked.
Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s.

Challenges and Potential Solutions for Recruitment and Retention of Hematopoietic Cell Transplantation Physicians: The National Marrow Donor Program’s.
Bone Marrow Transplantation for Diamond-Blackfan Anemia

Bone Marrow Transplantation for Diamond-Blackfan Anemia
Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission 

Outcome of Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation for Childhood Acute Lymphoblastic Leukemia in Third Remission 
Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-

Busulfan, Fludarabine, and Alemtuzumab As a Reduced Toxicity Regimen for Children with Malignant and Nonmalignant Diseases Improves Engraftment and Graft-versus-
Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,

Hematopoietic Stem Cell Transplantation for Refractory or Recurrent Non-Hodgkin Lymphoma in Children and Adolescents  Thomas G. Gross, Gregory A. Hale,
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 

Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.
NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric.

Similar presentations

Ads by Google